Tuberculosis (TB) is not a form of cancer. TB is a bacterial infection caused by a specific germ, while cancer is the uncontrolled growth of the body’s own cells. They are fundamentally different diseases with different causes, different treatments, and different outcomes. The confusion is understandable, though, because the two conditions can look remarkably similar on imaging scans and share many of the same symptoms.
Why TB and Cancer Are Different Diseases
TB is caused by bacteria that enter the body, usually through the lungs. Your immune system responds by walling off the bacteria in clusters of inflammatory tissue called granulomas. These granulomas can form masses that show up on chest X-rays and CT scans, sometimes looking nearly identical to a tumor.
Cancer, by contrast, starts when your own cells mutate and begin dividing without the normal controls that keep growth in check. There is no outside invader. The mass that forms is made of your body’s own tissue growing abnormally. This distinction matters because it determines everything about how each disease is treated: TB is cured with antibiotics, while cancer typically requires surgery, chemotherapy, radiation, or a combination.
Why the Two Get Confused
TB has been called a “great mimicker” and a “diagnostic chameleon” in medical literature because it so convincingly imitates cancer. The symptoms overlap heavily: cough, coughing up blood, weight loss, loss of appetite, fever, and breathlessness are common to both pulmonary TB and lung cancer. A doctor hearing that list of complaints cannot immediately rule out either condition.
Imaging adds another layer of confusion. On PET/CT scans, which measure metabolic activity in tissue, both TB lesions and cancerous tumors light up with high activity. The numerical values used to gauge how “hot” a lesion is on these scans often fall in the same range for TB and cancer, making it difficult to tell them apart from the scan alone. Newer imaging tracers are showing promise in distinguishing the two, but standard scans still struggle with this overlap.
A particularly tricky scenario involves miliary TB, a form where the infection spreads throughout the lungs and sometimes to the spine and other organs. On chest imaging, miliary TB produces numerous tiny nodules (1 to 3 millimeters) scattered across both lungs, a pattern that closely resembles cancer that has spread from one site to many. When TB reaches the spine, it can destroy bone in ways that look almost identical to spinal tumors on early imaging. MRI can help tell the two apart in later stages, but early on the differences are subtle.
How Doctors Tell Them Apart
Because imaging alone is often inconclusive, diagnosis usually comes down to laboratory testing. For TB, the gold standard is a culture, where a sample of sputum (mucus coughed up from the lungs), urine, or other body fluid is tested to see if TB bacteria grow from it. For cancer, the gold standard is a biopsy, where a small piece of tissue is removed and examined under a microscope for abnormal cells.
These are entirely different tests looking for entirely different things: one identifies a bacterium, the other identifies malignant cells. In some cases, doctors perform both when the initial findings are ambiguous. The location and type of mass, combined with the patient’s history, risk factors, and where they live, all feed into which tests are ordered first.
TB Can Raise Your Cancer Risk
While TB itself is not cancer, having had TB in the past does appear to increase the risk of developing lung cancer later. A large meta-analysis combining data from 32 studies found that people with a history of pulmonary TB were roughly twice as likely to be diagnosed with lung cancer compared to those who never had TB (an odds ratio of 2.09). Higher-quality studies within that analysis showed an even stronger association, with an odds ratio of 2.26.
The likely explanation involves the damage TB leaves behind. The infection causes repeated tissue injury and chronic inflammation in the lungs. Over time, this leads to scar tissue (fibrosis), and that scarred environment appears to promote conditions where cells are more likely to turn cancerous. Younger patients with a TB history showed a particularly strong statistical link to later lung cancer, suggesting that the longer someone lives with lung scarring, the more time there is for problems to develop.
This does not mean TB turns into cancer or that everyone who has had TB will get cancer. It means the lung damage from TB creates an environment where cancer is somewhat more likely to take hold, similar to how other forms of chronic lung injury raise cancer risk.
TB by the Numbers
TB remains one of the world’s most common infectious diseases. According to the 2024 WHO global report, an estimated 10.8 million new TB cases and 1.25 million deaths occurred worldwide in a single year. Roughly 400,000 of those new cases involved drug-resistant strains, which are harder to treat and account for about 150,000 deaths annually.
Treatment for standard, drug-susceptible TB typically takes 4 to 9 months of antibiotics, depending on the specific regimen. Latent TB, where the bacteria are present but not causing active disease, can be treated in as little as 3 to 4 months with shorter courses now preferred over older 9-month regimens. Untreated latent TB accounts for roughly 80% of active TB cases in the United States, which is why treatment at the latent stage is so important.
Cancer treatment, by comparison, looks completely different: surgery, radiation, chemotherapy, immunotherapy, or targeted drug therapy, often lasting months to years. The two diseases share almost nothing in how they are managed, which underscores just how different they are despite their surface-level resemblance.